🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

An Outcome Analysis of Primary Membranous Nephropathy

Recruitingn/aAges 18 Years - anyAllMario Negri Institute for Pharmacological Research
NCT06242327 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice. The study will primarily assess the long-term outcomes of patients with primary membranous nephropathy in the context of advances in treatment options.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults (≥18 years old) on the day of signing informed consent. * Diagnosis of primary membranous nephropathy * Nephrotic syndrome (proteinuria \>3.5 g/24 hours) * Written informed consent to the use of recorded data for research purposes. Exclusion Criteria: * Legal incapacity or limited legal capacity. * Any contraindication to treatment with rituximab or other monoclonal antibody
💊

What it tests

  • Not listed
📍

Where

2 sites
ASST HPG23 - Unità di Nefrologia
Bergamo, Italy
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
Ranica, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy